<VariationArchive VariationID="183240" VariationName="NM_020919.4(ALS2):c.4573dup (p.Val1525fs)" VariationType="Duplication" Accession="VCV000183240" Version="5" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-06-23" DateCreated="2020-02-24" MostRecentSubmission="2022-05-16">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="181373" VariationID="183240">
      <GeneList>
        <Gene Symbol="ALS2" FullName="alsin Rho guanine nucleotide exchange factor ALS2" GeneID="57679" HGNC_ID="HGNC:443" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2q33.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="201700267" stop="201780933" display_start="201700267" display_stop="201780933" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="202564985" stop="202645894" display_start="202564985" display_stop="202645894" Strand="-" />
          </Location>
          <OMIM>606352</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_020919.4(ALS2):c.4573dup (p.Val1525fs)</Name>
      <CanonicalSPDI>NC_000002.12:201706852:CCCC:CCCCC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>2q33.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="201706852" stop="201706853" display_start="201706852" display_stop="201706853" variantLength="1" positionVCF="201706852" referenceAlleleVCF="A" alternateAlleleVCF="AC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="202571575" stop="202571576" display_start="202571575" display_stop="202571576" variantLength="1" positionVCF="202571575" referenceAlleleVCF="A" alternateAlleleVCF="AC" />
      </Location>
      <OtherNameList>
        <Name>NM_020919.4(ALS2):c.4573dup</Name>
        <Name>p.Val1525fs</Name>
      </OtherNameList>
      <ProteinChange>V1525fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.202571579dup" Assembly="GRCh37">
            <Expression>NC_000002.11:g.202571579dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.201706856dup" Assembly="GRCh38">
            <Expression>NC_000002.12:g.201706856dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008775.1" sequenceAccession="NG_008775" sequenceVersion="1" change="g.79320dup">
            <Expression>NG_008775.1:g.79320dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_020919.4" sequenceAccession="NM_020919" sequenceVersion="4" change="c.4573dup" MANESelect="true">
            <Expression>NM_020919.4:c.4573dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_065970.2" sequenceAccession="NP_065970" sequenceVersion="2" change="p.Val1525fs">
            <Expression>NP_065970.2:p.Val1525fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_654" sequenceAccession="LRG_654">
            <Expression>LRG_654:g.79320dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_654t1" sequenceAccession="LRG_654t1">
            <Expression>LRG_654t1:c.4573dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_654p1" sequenceAccession="LRG_654p1" change="p.Val1525fs">
            <Expression>LRG_654p1:p.Val1525fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_020919.3" sequenceAccession="NM_020919" sequenceVersion="3" change="c.4573dupG">
            <Expression>NM_020919.3:c.4573dupG</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA273789" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="606352.0017" DB="OMIM" />
        <XRef Type="rs" ID="730882256" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_020919.4(ALS2):c.4573dup (p.Val1525fs) AND Amyotrophic lateral sclerosis type 2, juvenile" Accession="RCV000162072" Version="4">
        <ClassifiedConditionList TraitSetID="1212">
          <ClassifiedCondition DB="MedGen" ID="C1859807">Amyotrophic lateral sclerosis type 2, juvenile</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2014-03-25" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_020919.4(ALS2):c.4573dup (p.Val1525fs) AND Infantile-onset ascending hereditary spastic paralysis" Accession="RCV001089474" Version="4">
        <ClassifiedConditionList TraitSetID="1214">
          <ClassifiedCondition DB="MedGen" ID="C2931441">Infantile-onset ascending hereditary spastic paralysis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-05-04" SubmissionCount="2">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-05-04" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2020-02-24" MostRecentSubmission="2022-05-16">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">24562058</ID>
        </Citation>
        <DescriptionHistory Dated="2022-05-11">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2020-05-03">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="1214" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4157" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Infantile-onset ascending hereditary spastic paralysis</ElementValue>
                <XRef ID="Infantile-onset+ascending+hereditary+spastic+paralysis/3819" DB="Genetic Alliance" />
                <XRef ID="MONDO:0011797" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Spastic paralysis, infantile onset ascending</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Autosomal Recessive Juvenile Amyotrophic Lateral Sclerosis</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">IAHSP</ElementValue>
                <XRef Type="MIM" ID="607225" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="4914" />
                <XRef ID="4914" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">ALS2-related disorder involves retrograde degeneration of the upper motor neurons of the pyramidal tracts and comprises a clinical continuum of the following three phenotypes: Infantile ascending hereditary spastic paraplegia (IAHSP), characterized by onset of spasticity with increased reflexes and sustained clonus of the lower limbs within the first two years of life, progressive weakness and spasticity of the upper limbs by age seven to eight years, and wheelchair dependence in the second decade with progression toward severe spastic tetraparesis and a pseudobulbar syndrome caused by progressive cranial nerve involvement. Juvenile primary lateral sclerosis (JPLS), characterized by upper motor neuron findings of pseudobulbar palsy and spastic quadriplegia without dementia or cerebellar, extrapyramidal, or sensory signs. Juvenile amyotrophic lateral sclerosis (JALS or ALS2), characterized by onset between ages three and 20 years. All affected individuals show a spastic pseudobulbar syndrome (spasticity of speech and swallowing) together with spastic paraplegia. Some individuals are bedridden by age 12 to 50 years.</Attribute>
                <XRef ID="NBK1243" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000514976" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528540" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000249543" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301421</ID>
                <ID Source="BookShelf">NBK1243</ID>
              </Citation>
              <XRef ID="293168" DB="Orphanet" />
              <XRef ID="C2931441" DB="MedGen" />
              <XRef ID="MONDO:0011797" DB="MONDO" />
              <XRef Type="MIM" ID="607225" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1212" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="297" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Amyotrophic lateral sclerosis type 2, juvenile</ElementValue>
                <XRef ID="MONDO:0008780" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ALS, JUVENILE</ElementValue>
                <XRef Type="MIM" ID="205100" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Amyotrophic lateral sclerosis type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">ALSJ</ElementValue>
                <XRef Type="MIM" ID="205100" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ALS2</ElementValue>
                <XRef Type="MIM" ID="205100" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9470" />
                <XRef ID="9470" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">ALS2-related disorder involves retrograde degeneration of the upper motor neurons of the pyramidal tracts and comprises a clinical continuum of the following three phenotypes: Infantile ascending hereditary spastic paraplegia (IAHSP), characterized by onset of spasticity with increased reflexes and sustained clonus of the lower limbs within the first two years of life, progressive weakness and spasticity of the upper limbs by age seven to eight years, and wheelchair dependence in the second decade with progression toward severe spastic tetraparesis and a pseudobulbar syndrome caused by progressive cranial nerve involvement. Juvenile primary lateral sclerosis (JPLS), characterized by upper motor neuron findings of pseudobulbar palsy and spastic quadriplegia without dementia or cerebellar, extrapyramidal, or sensory signs. Juvenile amyotrophic lateral sclerosis (JALS or ALS2), characterized by onset between ages three and 20 years. All affected individuals show a spastic pseudobulbar syndrome (spasticity of speech and swallowing) together with spastic paraplegia. Some individuals are bedridden by age 12 to 50 years.</Attribute>
                <XRef ID="NBK1243" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15137" />
                <XRef ID="15137" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301421</ID>
                <ID Source="BookShelf">NBK1243</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301623</ID>
                <ID Source="BookShelf">NBK1450</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Orphanet, 2007">
                <URL>https://www.orpha.net/data/patho/Pro/en/Emergency_AmyotrophicLateralSclerosis.pdf</URL>
                <CitationText>Orphanet, Amyotrophic lateral sclerosis, 2007</CitationText>
              </Citation>
              <XRef ID="300605" DB="Orphanet" />
              <XRef ID="C1859807" DB="MedGen" />
              <XRef ID="MONDO:0008780" DB="MONDO" />
              <XRef Type="MIM" ID="205100" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="382253" SubmissionDate="2020-02-21" DateLastUpdated="2020-02-24" DateCreated="2015-03-04">
        <ClinVarSubmissionID localKey="606352.0017_AMYOTROPHIC LATERAL SCLEROSIS 2, JUVENILE" title="ALS2, 1-BP DUP, 4573G_AMYOTROPHIC LATERAL SCLEROSIS 2, JUVENILE" />
        <ClinVarAccession Accession="SCV000212105" DateUpdated="2020-02-24" DateCreated="2015-03-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-03-25">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In 2 sibs, born of consanguineous Turkish parents, with juvenile amyotrophic lateral sclerosis-2 (ALS2; 205100), Sheerin et al. (2014) identified a homozygous 1-bp duplication (c.4573dupG) in the ALS2 gene, resulting in a frameshift and premature termination (Val1525fs). The mutation, which was found by candidate gene sequencing, segregated with the disorder in the family and was not present in the Exome Variant Server database. In addition to ALS, both patients had generalized dystonia. Functional studies of the variant were not performed.</Attribute>
              <Citation>
                <ID Source="PubMed">24562058</ID>
              </Citation>
              <XRef DB="OMIM" ID="205100" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ALS2" />
          </GeneList>
          <Name>ALS2, 1-BP DUP, 4573G</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP DUP, 4573G</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="606352.0017" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">AMYOTROPHIC LATERAL SCLEROSIS 2, JUVENILE</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4903118" SubmissionDate="2022-05-04" DateLastUpdated="2022-05-16" DateCreated="2022-05-16">
        <ClinVarSubmissionID localKey="cfda911d-1586-4c9d-895c-0bc010f46acc" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV002507023" DateUpdated="2022-05-16" DateCreated="2022-05-16" Type="SCV" Version="1" SubmitterName="Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard" OrgID="506627" OrganizationCategory="laboratory" OrgAbbreviation="Broad RDG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The homozygous p.Val1525GlyfsTer17 variant in ALS2 was identified by our study in 1 individual with infantile-onset ascending hereditary spastic paralysis. The variant has been reported in 3 Turkish individuals with infantile-onset ascending hereditary spastic paralysis (PMID: 24562058, 33155358), segregated with disease in 1 affected relatives from 1 family (PMID: 24562058), and was absent from large population studies. This variant has been reported in ClinVar (Variation ID: 183240) as pathogenic by OMIM and as likely pathogenic by Cirak Lab, University Hospital Cologne. This variant is predicted to cause a frameshift, which alters the proteinâ€™s amino acid sequence beginning at position 1525 and leads to a premature termination codon 17 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the ALS2 gene is an established disease mechanism in autosomal recessive infantile-onset ascending hereditary spastic paralysis. The presence of this variant in 3 affected homozygotes and in 3 individuals with infantile-onset ascending hereditary spastic paralysis increases the likelihood that the p.Val1525GlyfsTer17 variant is pathogenic (PMID: 24562058). In summary, this variant meets criteria to be classified as pathogenic for infantile-onset ascending hereditary spastic paralysis in an autosomal recessive manner based on the predicted impact of the variant, its absence from control populations, and multiple homozygous occurrences in affected individuals. ACMG/AMP Criteria applied: PVS1, PM2, PM3, PP1 (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ALS2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_020919.4(ALS2):c.4573dup</Name>
            <Name>p.Val1525fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.12:g.201706856dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0011797" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431335</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1960406" SubmissionDate="2019-10-30" DateLastUpdated="2020-05-04" DateCreated="2020-05-04">
        <ClinVarSubmissionID localKey="NM_020919.3:c.4573dupG|OMIM:607225" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000998815" DateUpdated="2020-05-04" DateCreated="2020-05-04" Type="SCV" Version="1" SubmitterName="Cirak Lab, University Hospital Cologne" OrgID="506263" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-10-30">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_020919.3:c.4573dupG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="607225" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6482774</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4903118" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0011797" MappingRef="MONDO">
        <MedGen CUI="C2931441" Name="Infantile-onset ascending hereditary spastic paralysis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1960406" TraitType="Disease" MappingType="XRef" MappingValue="607225" MappingRef="OMIM">
        <MedGen CUI="C2931441" Name="Infantile-onset ascending hereditary spastic paralysis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="382253" TraitType="Disease" MappingType="Name" MappingValue="AMYOTROPHIC LATERAL SCLEROSIS 2, JUVENILE" MappingRef="Preferred">
        <MedGen CUI="C1859807" Name="Amyotrophic lateral sclerosis type 2, juvenile" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

